Supernus Pharmaceuticals Says US FDA Accepts NDA Resubmission for Potential Parkinson's Related Treatment Device

08:15 AM EDT, 08/19/2024 (MT Newswires) -- Supernus Pharmaceuticals (SUPN) said Monday that the US Food and Drug Administration had accepted its resubmission of a new drug application for its apomorphine infusion device, which is intended for continuous treatment of motor fluctuations in Parkinson's disease patients.

The company said the agency has set a target Prescription Drug User Fee Act date of Feb. 1.

Shares of Supernus were up 3.4% in recent premarket activity.

Price: 35.73, Change: +1.18, Percent Change: +3.42